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Abstract
Objective—The objective was to test the hypothesis that heart failure (HF) patients treated with
sertraline will have lower depression scores and fewer cardiovascular events compared to placebo.
Background—Depression is common among HF patients. It is associated with increased
hospitalization and mortality.
Methods—SADHART-CHF was a randomized, double-blind, placebo-controlled trial of
sertraline 50 to 200 mg/day versus matching placebo for 12 weeks. All participants also received
nurse facilitated support. Eligible patients were age ≥45 years with HF (LVEF ≤45%, NYHA class
II-IV) and clinical depression (DSM-IV criteria for current major depressive disorder). Significant
cognitive impairment, psychosis, recent alcohol or drug dependence, bipolar or severe personality
disorder, active suicidal ideation, and current antipsychotic or antidepressant medications were
exclusions. Primary endpoints were change in depression severity (Hamilton Depression Rating
Scale [HDRS] total score) and composite cardiovascular status at12-weeks.
Results—469 patients were randomized (N=234 sertraline, N=235 placebo). The mean ± SE
change from baseline to 12-weeks in the HDRS total score was -7.1 ± 0.5 (sertraline) and -6.8 ±
0.5 (placebo) (P<.001 from baseline, P=.89 between groups, mean change between groups -0.4,
95% CI -1.7, 0.92). The proportion whose composite cardiovascular score worsened, improved, or
was unchanged was 29.9%, 40.6%, and 29.5% in the sertraline group and 31.1%, 43.8%, and
25.1% in the placebo group (P=0.78).
Discussion—Sertraline was safe in patients with significant HF. However, treatment with
sertraline compared with placebo did not provide greater reduction in depression or improved




Heart failure is prevalent in both the United States and Europe. An estimated 5.7 million
Americans have heart failure (1), and there are at least 15 million patients with heart failure
in the 51 countries represented by the European Society of Cardiology (2). Heart failure is a
major cause of death and disability. Despite extensive therapeutic advances in
pharmacologic and device therapies for heart failure, morbidity and mortality remain high in
this population (3).
Depression is common in heart failure, with a reported prevalence of 21.5% (4), and it is one
of many factors that contribute to poor outcome in heart failure patients (5-8). Depression
has been independently associated with a poor quality of life, limited functional status, and
an increased risk of morbidity and mortality in this population (4;9-13).
Small studies have demonstrated improvements in depressive symptoms and quality of life,
and reductions in heart rate and plasma norepinephrine for heart failure patients treated with
antidepressants (14;15). Selective serotonin reuptake inhibitors (SSRIs) have been shown to
inhibit platelet function, promote endothelial stabilization, and possess anti-inflammatory
properties, although the clinical relevance of these properties have yet to be established
(16-24). These pharmacologic properties have led to the hypothesis that SSRIs may be
associated with cardiovascular benefits beyond their antidepressant effects. SSRIs have been
O'Connor et al. Page 2













shown to improve depression scores without adverse cardiovascular effects in several
studies conducted in patients with acute myocardial infarction, unstable angina, or stable
coronary artery disease (25;26). These data suggested the safety profile of sertraline was
adequate to permit testing in the heart failure population. The objective of the SADHART-
CHF (Sertraline Against Depression and Heart Disease in CHF) study was to evaluate the
safety and efficacy of sertraline in patients with depression and heart failure.
Methods
The SADHART-CHF trial was a randomized, double-blind trial of sertraline or placebo in
469 participants with heart failure and clinical depression. The study was conducted at 3
centers in the United States between 8/13/2003 and 3/3/2008. The protocol was reviewed
and approved by the appropriate institutional review board for each center. All participants
provided written, voluntary informed consent.
Eligibility Criteria
A complete description of the trial methodology has been published (27). Briefly, patients
≥45 years of age with LVEF ≤45% (within the previous 6 months), NYHA class II-IV heart
failure symptoms, and major depressive disorder (as determined by DSM-IV criteria) were
eligible for participation. Heart failure was confirmed at the time of presentation by clinical
heart failure specialist cardiologists. The main exclusion criteria included significant
cognitive impairment, alcohol or drug dependence within the previous year, psychoses,
bipolar disorder, severe personality disorder, active suicidal ideation, life-threatening
comorbidity (estimated 50% mortality within 1 year), and current use of antipsychotic or
antidepressant medications.
Study Design
SADHART-CHF tested the hypothesis that sertraline would improve symptoms of
depression and reduce cardiac events and morbidity/mortality in heart failure patients with
clinical depression to a greater extent than placebo. Eligible participants were randomized
1:1 to sertraline or matching placebo for the 12-week treatment period. The initial dose was
50 mg/day, and was increased in 50 mg/day increments based on the results of the BDI total
score and the clinical opinion of the examining investigator to a maximum of 200 mg/day.
For patients who were unable to tolerate higher doses, the dose could be decreased. The
minimum dose was 50 mg/day. Participants were categorized as completers if they
completed 12-weeks of study drug and assessment at the end of the 12-week intervention,
and non-completers if they discontinued study drug prior to 12-weeks. All participants,
regardless of whether or not they completed the 12-week treatment period were included in
all analyses as described in the statistical analysis section.
All participants also received nurse facilitated support, designed to build rapport and trust
with the study participants, ascertain compliance with the study protocol, re-evaluate
depression status, monitor suicidal ideation, and consult with study physicians on
appropriate patient management. Support was provided by nurses and other study personnel
with prior experience or training in clinical psychiatry, and they conducted interviews with
the study participants by telephone at 2, 4, 8, and 10 weeks and during in-clinic or home
visits at 6 and 12 weeks. Participants were also screened for suicidal ideation. The 17-item
Hamilton Depression Rating Scale (HDRS) was completed at baseline and at 2 week
intervals during the 12-week treatment phase.
All participants were referred to their primary care physician or a psychiatrist for follow-up
as indicated after the initial 12-week period. All participants were followed via phone or
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mail to ascertain clinical events and vital status every 2 weeks during the 12 week treatment
phase and at 6 months, 1 year, and annually thereafter until the last participant completed at
least 6-months of follow-up. The national death index was used to ascertain vital status of
participants who could not be reached via phone or mail.
Primary Endpoints
The primary endpoints of the study were change across time in the severity of depression
(measured by the HDRS total score) and composite cardiovascular status (Table 1), both
assessed at the end of the 12-week treatment period. Cardiovascular events and survival
during the short-term treatment phase and long-term follow-up were also assessed.
Adjudication of Cardiovascular Events
All cardiovascular events were adjudicated by three cardiologists with a heart failure sub-
specialty who were blinded to treatment assignment. All cardiovascular events resulting in a
procedure or hospitalization were adjudicated according to a pre-defined set of criteria. Each
event was reviewed by committee members separately and discussed during face-to-face
meetings. Discrepancies among reviewers were presented and discussed to achieve
consensus for all events.
Statistical Analysis
The study was designed to have at least 80% power to detect true between group differences
at the end of the 12-week treatment phase. A target enrollment of 500 was proposed during
the design stages based on estimates of: (a) 3-month cardiovascular mortality and re-
admission rates and (b) 3-month treatment response rate for depression. Based on published
findings, we predicted that the composite cardiovascular worsening rate would be 35% in
the sertraline group and 50% in the placebo group. Power calculations indicated that a
sample size of 440 (220 per treatment arm) would yield 80% power to detect a treatment
difference for the expected rates of the primary cardiovascular endpoint when applying a
two-sided, continuity-corrected chi-square test with the level of significance set at 0.05. The
depression literature suggested a response rate of 70-75% for sertraline and a placebo
response rate as high as 50%. A sample size of 200 (100 per treatment arm) would yield at
least 80% power to detect a treatment difference for expected response rates of 70% and
50% when using a two-sided, continuity-corrected chi-square test with the level of
significance set at 0.05. The primary depression outcome was the continuous HDRS total
scores collected over time rather than a dichotomized response score. The primary analysis
of this measure was a longitudinal analysis using a random coefficients regression model.
During the design stages, sufficient data were not available to estimate the treatment-by-time
effects for heart failure patients, so the sample size was based on estimated response rate. It
should be noted that continuous measures and longitudinal analysis methods often provide
greater power than chi-square analyses designed to test for differences in binary outcomes.
Thus, we concluded that a sample size of 440 would provide 80% or greater power for two
primary outcomes. The target enrollment was increased to 500 to adjust for early
termination.
Statistical analyses were performed by statistical personnel within Duke University Medical
Center, using SAS, version 9.1 (SAS Incorporated, Cary, NC). The primary analysis was
conducted according to the intention-to-treat principle. Although some participants did not
complete 12-weeks of treatment, all participants, regardless of whether or not they
completed 12-weeks of treatment, were included in all analyses. The complete analytic
methods have previously been described (27). Briefly, linear random coefficients regression
models adjusting for the effects of clinical site were used as a longitudinal data analysis
method to examine the trajectory of change in HDRS total scores over the acute 12 week
O'Connor et al. Page 4













treatment period between the two treatment arms. This methodology allows all participants
with data for at least one time point to be included (n=469) and eliminates the issue of
dealing with missing data. This hierarchical mixed model included the fixed effects of
treatment, the natural log of time and natural log of time squared, their interactions with
treatment, and site, as well as the random effects of patient, patient-by-time, and square of
patient-by-time. Tests for differences of proportions were used to examine the composite
cardiovascular status outcome at the end of acute treatment. Chi-square tests were used to
test for overall treatment differences, with a Mantel-Haenszel test performed to examine
treatment differences when controlling for clinical site. The primary analyses were
conducted on the tri-level cardiovascular status outcome.
A per-protocol analysis was also performed. This analysis included only those participants
who completed 12-weeks of treatment (n=290), and it was conducted on the change in
HDRS over the 12 week period and on the composite cardiovascular status. The analyses
were similar to those conducted on the intention-to-treat sample.
Role of the Funding Source
The SADHART-CHF study was funded by the National Institute of Mental Health (NIMH)
Bethesda, Maryland. The NIMH did not participate in study development, conduct, data
collection, analysis, interpretation, or writing of the study report. The NIMH was given an
opportunity to review the manuscript prior to submission, but they did not participate in the
decision to submit for publication. Sertraline was supplied by Pfizer, Inc., New York, New
York. Pfizer had no other role in any aspect of the study.
Results
Participant Characteristics
A total of 469 participants were enrolled, and their flow through the trial is shown in Figure
1. Baseline characteristics of the study population by treatment group are shown in Table 2.
Study Drug Treatment and Discontinuation
A total of 234 participants were randomized to sertraline. Of these, 138 were classified as
completers. The mean ± SD number of days treated was 86.1 ± 5.7. The remaining 96
participants (non-completers) received study drug for a mean ± SD of 36.7 ± 26.2 days. The
mean last dose of sertraline was 65 ± 29 mg/day achieved in those completing 12-weeks of
treatment, and 63 ± 29 mg/day in those who did not. In the placebo group, 152 participants
of the 235 randomized completed the 12-week treatment period and received study drug for
86.2 ± 5.3 days (mean ± SD). The remaining 83 participants were non-completers and
stopped study drug after 34.7 ± 26.1 days of treatment. The mean dose of matching placebo
was 92 ± 52 mg/day achieved in those completing 12-weeks of treatment, and 67 ± 35 mg/
day in those who were non-completers. The reasons for study drug withdrawal are given in
Figure 1.
12-Week Acute Phase Endpoint
HDRS Total Score—The mean ± SD HDRS total score at baseline was 18.3 ± 5.5 in the
sertraline group and 18.3 ± 5.4 in the placebo group. Figure 2 displays the trajectory of
improvement in the raw total scores of HDRS across the treatment phase. Both groups
exhibited a significant reduction in the HDRS total score (time P<.001; time squared P<.
001), but this reduction in HDRS total score was not significantly different between groups
(mean change -0.4, 95% CI -1.7-0.9, treatment-by-time interaction, P=.89; treatment-by-
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time squared interaction P=0.76). The mean ± SE change from baseline to 12-weeks was
-7.1 ± 0.5 and -6.8 ± 0.5 in the sertraline and placebo groups, respectively.
A total of 8.8% of patients were titrated up to 200mg/day, 9.0% to 150mg/day, 20.6% to
100mg/day, and 61.7% were maintained at 50mg/day. The HDRS scores at baseline vs. 12-
weeks for all the completers among these four groups were as follows: 21.0 vs. 15.6 (200
mg/day); 20.2 vs. 9.9 (150 mg/day); 18.2 vs. 7.6 (100 mg/day); and 17.6 vs. 4.4 (50 mg/
day). There was no treatment assignment by dose interaction, p=0.281.
A longitudinal analysis of HDRS was performed in the subgroup of 64 participants with a
history of depression and a HDRS score >17 at baseline. The results were similar to the
intention-to-treat analysis. The mean change in HDRS from baseline to 12-weeks was -6.2
(P=0.002) in the sertraline group and -5 (P=0.001) in the placebo group. There was no
difference in change scores between groups (1.3, 95% CI -3.5, 6.1; P=0.59). Again, there
was no treatment by dose interaction.
Composite Cardiovascular Status—In the sertraline group, the composite
cardiovascular status worsened in 29.9% (70/234), improved in 40.6% (95/234), and
remained unchanged in 29.5% (69/234). In the placebo group, 31.1% (73/235) worsened,
43.8% (103/235) improved, and 25.1% (59/235) were unchanged. The proportion of
participants classified as worsened, improved, or unchanged did not differ significantly
between groups (P=.78).
The 12-week mortality rate was 7% in the overall population. No differences were observed
between groups in individual components of the composite score, including all cause
mortality, cardiovascular death, non-fatal cardiovascular events, heart failure hospitalization,
or combinations of these outcomes (Table 3).
The total number of days alive during the 12-week acute phase was similar in both groups,
86.1 ± 15.7 in the sertraline group, and 86.2 ± 15.4 in the placebo group (P=.61). The
distribution of change in NYHA class was also similar among groups. NYHA class
worsened in 61 (34.9%) of the sertraline group and 73 (41%) of the placebo group, and it
was unchanged or improved in 114 (65.1%) of the sertraline group and 105 (59%) of the
placebo group.
An as per-protocol analysis (including only those participants who completed 12-weeks of
treatment) was also performed. The results for change in HDRS and composite
cardiovascular score were similar to the findings of the intention-to-treat analysis.
Tolerability and Safety—A significantly higher proportion of participants in the
sertraline arm withdrew from the treatment phase because of side effects that were believed
to be study drug related (N=27/234; 11.5%) as compared to the placebo group (N=14/235;
6.0%) (P=.03). Nausea (9/41 [21.9%] vs. 1/41 [2.4%]) and dizziness (4/41 [9.8%] vs. 2/41
[4.9%]) were the most common side effects reported with a higher frequency in the
sertraline arm. Serious adverse events were not statistically different between the groups
(Table 4). Two participants in the placebo group developed significant suicidal ideations
during the acute treatment phase. There were no suicide attempts or completed suicides.
Long-term Follow-up Endpoints
Participants were followed for 798 ± 493 days (mean ± SD) during the long-term follow-up
phase (sertraline group 788 ± 480 days, placebo group 808 ± 506 days, P=.68). All cause
mortality was not different between groups. A total of 68 participants (29.1%) in the
sertraline group died compared to 61 (26%) in the placebo group. In the Cox model adjusted
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for site, the hazard ratio for survival was not significantly different between the two
treatment groups (HR 1.3, 95% CI 0.66-2.58; P=.45). Non-fatal cardiovascular events were
also similar (Table 5).
Discussion
All participants in SADHART-CHF demonstrated improvements in depression scores from
baseline. Multiple reasons may be responsible for the lack of an observed additive benefit
with sertraline. Placebo effects are common in anti-depressant trials. One analysis of 75 anti-
depressant trials found a 30% placebo response rate, defined as the number of placebo
treated patients who had a ≥50% reduction in the HDRS score (28). The placebo response in
this study may have been enhanced by the nursing support provided to all participants. An
additive benefit for sertraline on depression scores was not detected. It is possible that the
close cardiovascular follow-up coupled with the nursing staff interactions improved mood
disorders to a degree sufficient to blunt any sertraline effect. It is also possible that the
mechanism of depression and mood disorders differs in the heart failure population, such
that their response to traditional anti-depressant pharmacotherapy is inadequate.
The level of depression in our study may not have been severe enough to respond to
sertraline therapy. A recent meta-analysis suggests that antidepressants may have minimal
effect among patients with HDRS scores <23; the baseline HDRS scores in SADHART-
CHF were 19.9 and 18.4 in the sertraline and placebo groups, respectively (29).
The mean doses of sertraline achieved in SADHART-CHF may have been insufficient to
demonstrate efficacy. Additionally, the pharmacokinetics of many drugs may be altered in
the setting of acute decompensation; it is possible that higher doses of sertraline may be
needed in patients with a recent episode of acute decompensated heart failure to overcome
the lower absorption that can occur in states of significant volume overload or reduced
cardiac output (and decreased gastrointestinal perfusion) states. There are no data evaluating
the extent to which sertraline pharmacokinetics may be altered in acute heart failure, but this
hypothesis may be worth exploring in future studies.
Similarly, in the SADHART trial of sertraline in patients with acute myocardial infarction or
unstable angina, sertraline's overall effect size on the depression endpoint was small and
only significant in the subset of patients with recurrent depression (25). These findings may
reflect a true lack of efficacy for sertraline in these populations whose depression may not be
severe enough to benefit from sertraline or other antidepressants (29). The pathophysiology
of depression in patients with heart failure or acute myocardial infarction/unstable angina
patients may have unique characteristics that may be less responsive to antidepressant
therapy.
These data indicate that heart failure patients with evidence of depression may benefit from
psychosocial supportive care delivered by clinically experienced personnel. Based on the
findings of SADHART-CHF, there is no conclusive evidence that antidepressants provide
additional benefit to supportive care in these patients. The use of antidepressant agents
should likely be reserved for patients who do not respond to supportive care.
The SADHART-CHF study confirmed that patients with depression and heart failure remain
at high risk of adverse outcome, with a mortality rate of 7% at 12 weeks. This high event
rate is not an isolated finding; we have previously reported a 13% mortality rate at 12-weeks
in a cohort of heart failure patients with major depression (30). This mortality rate is higher
than would be expected based on the population's heart failure characteristics alone,
considering the annual mortality rate reported in a similar outpatient heart failure population
with primarily NYHA class II and III symptoms was 8.1-8.8% (31). The SADHART-CHF
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mortality rate is similar to the 60-90 day post-discharge mortality rate of 8.6% reported in
patients hospitalized for heart failure in the OPTIMIZE-HF registry (32). This elevated
short-term mortality rate may be due to the presence of depression, and it reinforces the need
to find more effective treatment and management approaches for depression in patients with
heart failure.
Sertraline did not influence short or long-term cardiovascular events or survival in this study
as compared to the placebo. The proportion of participants whose cardiovascular status
worsened, improved, or was unchanged was similar among treatment groups. Fatal and non-
fatal cardiovascular events were also similar between groups. Thus, the ancillary properties
of SSRIs (16-24) did not translate into cardiovascular benefit, at least in this short-term
study.
A large, ongoing trial will provide further evidence to guide the management of patients
with heart failure and depression (18). The Morbidity, Mortality and Mood in Depressed
Heart Failure patients (MOOD-HF) study plans to randomize 700 patients to escitalopram
10-20 mg/day or placebo for 12-24 months. The primary endpoint is the time to first death
or hospitalization (18). The results are expected in fourth quarter 2010 (source: http://
isrctn.org, registry number 33128015).
The SADHART-CHF results should be evaluated in the context of several limitations. Nurse
support may have contributed to the placebo response and improvement in depression
scores, limiting the ability to detect a difference between groups. The non-completer rate
was approximately twice the rate assumed in the sample size calculations. However, even a
larger sample would be unlikely to affect the results, given the small observed differences
between groups. Finally, a short-term duration of therapy may have been insufficient to fully
demonstrate the potential effects of sertraline on cardiovascular outcomes.
In conclusion, depression in patients with heart failure is associated with substantial
mortality. Sertraline did not adversely affect cardiovascular outcomes in this population, and
it may be an appropriate therapeutic strategy in patients who remain depressed despite non-
pharmacologic interventions and who otherwise have an indication for sertraline. Many
patients with depression and heart failure who have coronary heart disease may be
candidates for depression treatment on the basis of their coronary heart disease alone (33).
Further research is needed to determine the optimal combination of pharmacologic and non-
pharmacologic treatment of depression in patients with heart failure.
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MOOD-HF Morbidity, Mortality and Mood in Depressed Heart Failure patients
NIMH National Institutes of Mental Health
NYHA New York Heart Association
SADHART – CHF Sertraline Against Depression and Heart Disease in CHF
SSRI Selective serotonin reuptake inhibitor
O'Connor et al. Page 11













Figure 1. Participant Flow Through the Trial
Completers were participants who completed 12-weeks of study drug and assessment at the
end of the 12-week intervention. Non-completers were participants who discontinued study
drug prior to 12-weeks. Participants were considered non-compliant if they did not take the
study medication for ≥14 consecutive days.
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Figure 2. Change in HDRS from Baseline to Week 12
Based on raw HDRS scores. This plot displays the change in HDRS total scores by week in
the study. The primary analysis was conducted based on the natural log of days, with a P=.
89.
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Worsened Any of the following conditions occur after randomization
• All cause death
• Occurrence of one or more of the following primary CV events:
– exacerbation of heart failure




– transient ischemic attack
– stroke/cardiovascular accident
– complications of cardiac medications or cardiac procedures
• Permanent discontinuation of double-blind study drug due to CV reasons
• Permanent discontinuation of double-blind study drug because of refusal to participate, withdrawal of consent, or
other administrative reasons AND at least one of the following occurred during the post-randomization period
– primary CV event on or prior to discontinuation of double-blind study drug
– increase of NYHA class on or prior to discontinuation of double-blind study drug
– death within 7 days following discontinuation of double-blind study drug
Improved The criteria for “worsened” has not been previously met AND at least one of the following conditions occurred at the last
assessment completed during the post-randomization period:
• Improvement in NYHA functional class
• Heart failure status (as determined by the clinician CGI-I score) is judged to be moderately-to-markedly improved
Unchanged Participant is neither improved or worsened





















Age, mean (SD), y 62.9 (10.5) 61.4 (11.1)
Women, No. (%) 101 (43.2) 89 (37.9)
Race, No. (%)
 White 131 (56) 136 (57.9)
 African American 92 (39.3) 82 (34.9)
 Hispanic 0 (0) 2 (0.9)
Heart Failure Characteristics
NYHA Class, No. (%)
 I 0 (0) 0 (0)
 II 71 (30.3) 61 (26)
 III 109 (46.6) 114 (48.5)
 IV 54 (23.1) 60 (25.5)
LVEF, mean (SD) 31.3 (9.5) 29.5 (10.1)
Ischemic etiology, No. (%) 163 (69.7) 163 (69.4)
≥1 heart failure hospitalization in previous 12 months, No. (%)* 134 (57.3) 158 (67.2)
Depression Characteristics
BDI Total Score, mean (SD) 19.9 (7.2) 18.4 (6.6)
HDRS Total Score, mean (SD) 18.3 (5.5) 18.3 (5.4)
Depression History
Antidepressant Use at Recruitment, No. (%) 19 (8.1) 15 (6.4)
Major depression, No. (%) 39 (16.7) 25 (20.6)
Cardiovascular History
Coronary artery disease, No. (%) 172 (73.5) 159 (67.7)
Myocardial infarction, No. (%) 122 (52.1) 105 (44.7)
Arrhythmia, No. (%) 94 (40.2) 106 (45.1)
Hypertension, No. (%) 212 (90.6) 200 (85.1)
Hyperlipidemia, No. (%) 180 (76.9) 183 (77.9)


















Diabetes, No. (%) 126 (53.8) 108 (46)
Renal disease, No. (%) 81 (34.6) 87 (37)
PCI/Stent, No. (%) 83 (35.5) 88 (37.4)
Coronary artery bypass graft surgery, No. (%) 82 (35) 78 (33.2)
Implantable cardioverter defibrillator, No. (%) 45 (19.2) 45 (19.1)
Permanent pacemaker, No. (%) 17 (7.3) 12 (5.1)
Cardiovascular Medications
ACE-inhibitor, No. (%) 165 (71.4) 165 (70.2)
Angiotensin receptor blocker, No. (%) 22 (9.4) 17 (7.2)
Beta blocker, No. (%) 202 (86.3) 194 (82.6)
Loop diuretic, No. (%) 144 (61.5) 147 (62.6)
Digoxin, No. (%) 36 (15.4) 44 (18.7)
Statin, No. (%) 168 (71.8) 158 (67.2)
Aspirin, No. (%) 197 (84.2) 194 (82.6)
*
P=.03
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Table 3






All cause mortality, No. (%) 18 (7.7) 15 (6.8) .58
Cardiovascular death, No. (%) 16 (6.8) 10 (4.3) .59
Non-fatal cardiovascular event, No. (%) 47 (20.1) 55 (23) .39
Acute myocardial infarction, No. (%) 1 (0.4) 0 .31
Arrhythmia, No. (%) 4 (1.7) 6 (2.6) .53
Cardiac syncope, No., (%) 0 1 (0.4) .32
Cerebrovascular accident, No. (%) 2 (0.8) 1 (0.4) .56
Exacerbation of heart failure, No. (%) 19 (8.1) 30 (12.8) .1
Unstable angina, No. (%) 7 (3) 5 (2.1) .55
Other non-fatal cardiovascular event, No. (%) 14 (6) 12 (5.1) .68
All cause mortality or non-fatal cardiovascular event,
No. (%)
65 (29.4) 70 (29.8) .63
Heart failure hospitalization or death, No. (%) 37 (15.8) 45 (19.2) .34
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Table 4








Cardiovascular, No. (%) 69 (35.6)* 72 (37.1)* .79
Psychiatric† 0 (0)* 2 (1)* .16
Non-CV and Non-psychiatric 29 (14.9)* 22 (11.3)* .30
*
Percentages are calculated from the total SAEs (using N=194 as the denominator)
†
No attempted or completed suicide
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Table 5






Acute myocardial infarction, No. (%) 10 (4.3) 8 (3.4) .63
Arrhythmia, No. (%) 17 (7.3) 20 (8.5) .61
Cardiac syncope, No., (%) 6 (2.6) 6 (2.6) .99
Cerebrovascular accident, No. (%) 10 (4.3) 4 (1.7) .1
Exacerbation of heart failure, No. (%) 64 (27.4) 68 (28.9) .7
Unstable angina, No. (%) 23 (9.8) 19 (8.1) .51
*Other cardiovascular event, No. (%) 50 (21.4) 59 (25.1) .34
*
Includes: wound infection, peripheral vascular disease, acute renal failure, drainage drive line, hypertensive urgency, presyncope, accelerated
hypotension, hypotension, deep vein thrombosis, prerenal azotemia, graft thrombosis, non-unstable angina chest pain.
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